Protalix BioTherapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Protalix BioTherapeutics Inc.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Protalix BioTherapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Protalix BioTherapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Protalix BioTherapeutics Inc. is PLX:xase. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Protalix BioTherapeutics Inc. has its primary listing on NYSE American. You can trade Protalix BioTherapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Protalix BioTherapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Protalix BioTherapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Protalix BioTherapeutics Inc..